Loading
A phase 3 trial of Luspatercept in myelodysplastic syndromes / neoplasms and myeloproliferative neoplasms, run by Celgene, now recruiting.
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials is a phase 3 interventional study registered as NCT04064060 by Celgene, with 665 participants planned, started 2019-08-12 and due to reach its primary completion in 2028-05-12. Interventions recorded: Luspatercept.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Luspatercept, Transfusion support and anaemia management, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Bristol Myers Squibb.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Bristol Myers Squibb and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/